For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG GY019

Trial Overview

Official Title

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Study Purpose

To determine how well the oral drug Letrozole works with or without Paclitaxel and Carboplatin in treating stage II-IV low grade cancer of the ovary or peritoneum.

Diagnosis

Stage II-IV low grade serous carcinoma of the ovary or peritoneum.

Eligibility

Must have had surgery within 8 weeks prior to starting chemotherapy.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: You will get Paclitaxel, Carboplatin and Letrozole
  • Group 2: You will get Letrozole

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
GY019